Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Streptococcus Salivarius Evol12® in Improving Quality of Life in Locally Advanced Head and Neck Cancer Treated With Radio(Chemo)Therapy: SMILE (SMILE)

18 de noviembre de 2026 actualizado por: Aurora Mirabile, IRCCS San Raffaele

Streptococcus Salivarius Evol12® in Improving Quality of Life In Locally Advanced Head and Neck Cancer Treated With radiochEmotherapy: SMILE, a Monocentric National Randomized Double Blind Interventional Study

The clinical study will involve the use of a dietary supplement based on the oral probiotic strain Streptococcus salivarius Evol12® in patients with head and neck cancer undergoing radiochemotherapy, with the aim of improving their quality of life. The hypothesis is that, as already outlined in scientific literature, modifying the oral microbiota through the use of the commensal S. salivarius, increasing its concentration and reducing the main pathogens in the oral cavity, may protect these patients and reduce the impact on their quality of life . A discovery of this kind would allow patients with head and neck cancer to be treated not only with standard therapy but also with treatments designed to modify the oral microbiota, which is not currently taken into consideration, in order to improve these patients' quality of life and compliance with treatment. Compared to the S. salivarius K12 strain, the S. salivarius eK12 (Evol12®) strain has a genome that is entirely similar to K12, but with a hypothetically greater antibacterial activity due to the presence of two specific genetic differences which allow for increased release of a bacteriocin: the salivabactin. Streptococcus salivarius eK12 (Evol12®) has undergone mutagenesis, acute toxicity, and subchronic toxicity studies in animals, conducted according to OECD guidelines by a GLPcertified laboratory, confirming its safety of use and absence of toxicity (In vitro and In vivo safety evaluation of Streptococcus salivarius eK12, a genetically modified dietary probiotic derived from the oral probiotic S. salivarius K12). In addition, a randomized, double-blind, placebo-controlled clinical trial conducted in healthy adults has been published, demonstrating its complete safety of use even at high dosages.

Descripción general del estudio

Estado

Aún no reclutando

Tipo de estudio

Intervencionista

Inscripción (Estimado)

170

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

  • Nombre: Aurora Mirabile Medical oncologist
  • Número de teléfono: +39 02 2643 3526
  • Correo electrónico: mirabile.aurora@hsr.it

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  1. Participants are willing and able to give informed consent for participation in the study.
  2. Aged >=18 years
  3. Patients diagnosed with non-metastatic head and neck malignant tumors, with an Eastern Cooperative Oncology Group performance status of ≤2, planning to receive definitive RT or postoperative adjuvant RT concomitant to cisplatin.
  4. Patient affected by squamocellular carcinoma of oral cavity, larynx, hypopharynx, oropharynx and undifferentiated or squamocellular carcinoma of nasopharynx.
  5. Patients eligible for to receive definitive RT or postoperative adjuvant RT concomitant to cisplatin.

Exclusion Criteria:

  1. Patients with a history of allergy to probiotics or severe allergic constitution
  2. Use of antibiotics/antifungal drugs within 1 month or antimicrobial mouthwash within 1 week before the study
  3. Poor oral hygiene and/or severe periodontal diseases (CTCAE 5.0 Grading >/=2)
  4. Any previous RT to the head and neck region
  5. Those deemed unsuitable for the study by the investigators (concomitant with any other severe diseases)
  6. Allergies: history of known allergies to probiotics or to product excipients.
  7. Recent antimicrobial therapies: use of systemic antibiotics or antifungals within 1 month, or antimicrobial mouthwashes within 1 week.
  8. Oral cavity conditions: severely compromised oral hygiene or severe periodontal disease.
  9. Previous radiotherapy: any prior radiotherapy (RT) to the head and neck region.
  10. Severe comorbidities: severe concomitant diseases that make the patient unsuitable according to clinical judgment.
  11. Pregnancy and breastfeeding
  12. Contraindication related to probiotic composition
  13. Primary sites different from the ones described in inclusion criteria
  14. Patient unfit to cisplatin
  15. Immunocompromised Patients

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Cuidados de apoyo
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Doble

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Comparador de placebos: placebo group

The placebo lozenges will be identical in appearance, taste, and composition, but will contain only excipients (sugar and starch), without any active bacteria.

Participants will be instructed to slowly dissolve one lozenge in the mouth three times daily (morning, afternoon, and evening) throughout the entire radiotherapy (RT) period. Patients will also be advised to avoid eating, drinking, or performing oral hygiene procedures for at least one hour after administration

Experimental: group treated with probiotic: Streptococcus salivarius Evol12®

The investigational product (Bactoblis® Evol, containing the probiotic strain Streptococcus salivarius Evol12®) will be provided in the form of oral lozenges, each containing ≥ 1 × 10⁹ colony-forming units (CFU) of viable S. salivarius Evol12® cells as the active ingredient.

Participants will be instructed to slowly dissolve one lozenge in the mouth three times daily (morning, afternoon, and evening) throughout the entire radiotherapy (RT) period.

Participants will be instructed to slowly dissolve one lozenge in the mouth three times daily (morning, afternoon, and evening) throughout the entire radiotherapy (RT) period. Patients will also be advised to avoid eating, drinking, or performing oral hygiene procedures for at least one hour after administration, in order to ensure optimal mucosal contact and promote probiotic colonization.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
EORTC QLQ-H&N35 score
Periodo de tiempo: It will be assessed before treatment, 3 weeks, 8 weeks and subsequently for up to 8 weeks.

Change in quality of life assessed using the EORTC QLQ-H&N35 scale before treatment, 3 weeks, at the end of treatment (8 weeks) and thereafter for up to 8 weeks.

It will be assessed before treatment, 3 weeks, 8 weeks and subsequently for up to 8 weeks.

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
days
Periodo de tiempo: It will be assessed before treatment, 3 weeks, 8 weeks and subsequently for up to 8 weeks.

Time to onset (days) of WHO grade ≥2 and ≥3.

It will be assessed before treatment, 3 weeks, 8 weeks and subsequently for up to 8 weeks.
days
Periodo de tiempo: It will be assessed before treatment, 3 weeks, 8 weeks and subsequently for up to 8 weeks.

Duration (days) of WHO grade ≥2 and ≥3.

It will be assessed before treatment, 3 weeks, 8 weeks and subsequently for up to 8 weeks.
Percentage
Periodo de tiempo: It will be assessed before treatment, 3 weeks, 8 weeks and subsequently for up to 8 weeks.

Rate of RT/chemotherapy interruptions, dose reduction or delay due to toxicity.

It will be assessed before treatment, 3 weeks, 8 weeks and subsequently for up to 8 weeks.
Numeric Rating Scale (NRS)
Periodo de tiempo: It will be assessed before treatment, 3 weeks, 8 weeks and subsequently for up to 8 weeks.

Change in Pain Scores Over Time, assessed using the Numeric Rating Scale (NRS; 0-10), where 0 indicates no pain and 10 indicates the worst pain imaginable. Higher scores indicate greater pain intensity and a worse outcome.

It will be assessed before treatment, 3 weeks, 8 weeks and subsequently for up to 8 weeks.
Percentage
Periodo de tiempo: It will be assessed before treatment, 3 weeks, 8 weeks and subsequently for up to 8 weeks.

Percentage of patients requiring enteral or parenteral nutritional support according to the percentage of weight loss (≥5% o ≥10%).

It will be assessed before treatment, 3 weeks, 8 weeks and subsequently for up to 8 weeks.
days
Periodo de tiempo: It will be assessed before treatment, 3 weeks, 8 weeks and subsequently for up to 8 weeks.

duration of RT/chemotherapy interruptions, dose reduction or delay due to toxicity.

It will be assessed before treatment, 3 weeks, 8 weeks and subsequently for up to 8 weeks.

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Estimado)

1 de enero de 2027

Finalización primaria (Estimado)

1 de enero de 2027

Finalización del estudio (Estimado)

1 de diciembre de 2028

Fechas de registro del estudio

Enviado por primera vez

4 de noviembre de 2026

Primero enviado que cumplió con los criterios de control de calidad

18 de noviembre de 2026

Publicado por primera vez (Actual)

20 de noviembre de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

20 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

18 de noviembre de 2026

Última verificación

1 de noviembre de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir